Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker AnalysesMarket Beat·Aug 19 at 05:03 PMCLNN-3.76%
Clene Reports Second Quarter 2026 Financial Results and Recent Operating HighlightsUnusual Whales·Aug 14 at 07:32 AMCLNN-3.76%
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of "Moderate Buy" from AnalystsMarket Beat·Aug 11 at 05:29 AMCLNN-3.76%
Buy Rating Reaffirmed on CNM-Au8 ALS Progress, Regulatory Momentum; $31 Price Target MaintainedTip Ranks·Aug 10 at 11:35 AMCLNN-3.76%
Clene says ALS biomarker analyses show CNM-Au8 survival benefit in NfL respondersPUBT·Aug 10 at 07:08 AMCLNN-3.76%
Clene to present at Canaccord Growth Conference, host investor meetingsPUBT·Jul 29 at 07:32 AMCLNN-3.76%
Clene Inc. (NASDAQ:CLNN) Receives Consensus Rating of "Moderate Buy" from AnalystsMarket Beat·Jul 17 at 05:29 AMCLNN-3.76%STT+0.03%
Top Nanotechnology Stocks Worth Watching - July 11thMarket Beat·Jul 11 at 01:02 PMONTO-0.42%NVEC+1.21%
Clene Extends 2025 Convertible Notes to 2027, Defers $150,000 Monthly PaymentsTradingView·May 22 at 03:43 PMCLNN-3.76%
